TOI - NASDAQ
The Oncology Institute, Inc.
$4.59
-7.8%The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
At a Glance
Live SnapshotThe Oncology Institute, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Thin margins leave little room for error. Cost management and pricing strategy are critical.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
The Oncology Institute, Inc. Income Statement
TOI • NASDAQ
| The Oncology Institute, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
502.7M | 393.4M | 324.2M | 252.5M | 203M | 187.5M | 155.4M | 113.2M | |
GROSS PROFIT | ||||||||
(433.2M) | (339.4M) | (264.7M) | (200.4M) | (162.2M) | (150.6M) | (125.5M) | (86.9M) | |
69.5M | 54M | 59.6M | 52.1M | 40.8M | 36.9M | 29.9M | 26.3M | |
OPERATING INCOME | ||||||||
(105.6M) | (114.1M) | (136.6M) | (134M) | (86.7M) | (45.1M) | (32.6M) | (21.5M) | |
(105.6M) | (0.0) | (0.0) | (0.0) | (0.0) | (41.9M) | (29.6M) | (20.4M) | |
-36.1M | -60.1M | -77M | -82M | -45.9M | -8.2M | -2.6M | 4.8M | |
PRE-TAX INCOME | ||||||||
(11.3M) | (7.5M) | (6.8M) | (4.1M) | (320K) | (347K) | (3.4K) | (1.6K) | |
-11.3M | -7.5M | -6.8M | -4.1M | -320K | -347K | -3.4K | -1.6K | |
(0.0) | (114.1M) | (136.6M) | (134M) | (86.7M) | (3.2M) | (2.9M) | (1.1M) | |
-24.7M | -4.5M | -6.1M | 81.9M | 34.3M | -6.6M | 6.6K | 71.2K | |
-60.7M | -64.7M | -83.1M | -91K | -11.6M | -14.8M | -2.6M | 4.9M | |
NET INCOME | ||||||||
-131K | (0.0) | -36K | -243K | -671K | -492.8K | (1.4M) | (912.7K) | |
-60.6M | -64.7M | -83.1M | 152K | -10.9M | -14.3M | -4M | 3.9M |
SEC Filings
TOI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 22, 2026 | May 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 13, 2026 | March 13, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 07, 2026 | January 02, 2026 | 2026 |
Related Guides
Continue your TOI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.